Chemomab Therapeutics Ltd. (CMMB) Thursday announced positive results from the Phase 2 SPRING trial of monoclonal antibody, CM-101, in patients with primary sclerosing cholangitis. The results show a proof-of-concept for CM-101, the company claimed.
The company said the trial with CM-101 achieved its primary endpoint of safety and tolerability and demonstrated anti-fibrotic, anti-inflammatory, and anti-cholestatic effects across a broad range of secondary efficacy endpoints. The data also showed statistically significant improvement in liver stiffness, a key marker.